SCHEMBL4076464

SCHEMBL4076464

C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)c1ccc(CNCc2ccccn2)cc1)c1cccc2ccccc12

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.78
EPHX2 P34913 2/20 0.41
METAP2 P50579 2/20 0.39
METAP1 P53582 2/20 0.39
CASR P41180 1/20 0.39
MAPK14 Q16539 1/20 0.39
MCHR1 Q99705 3/20 0.39
BMP1 P13497 2/20 0.39
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
PADI4 Q9UM07 1/20 0.38
PADI2 Q9Y2J8 1/20 0.38
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6017943 0.92 CXCR4 (0.67) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL29580087 0.88 CXCR4 (1.00) CXCR4MCHR1PADI4PADI2
SCHEMBL6017976 0.87 CXCR4 (0.61) CXCR4EPHX2METAP2METAP1MCHR1
SCHEMBL6652983 0.85 CXCR4 (0.70) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6652769 0.85 CXCR4 (0.74) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6656486 0.85 CXCR4 (0.74) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6656081 0.85 CXCR4 (0.74) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6654961 0.85 CXCR4 (0.74) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6658566 0.84 CXCR4 (0.71) CXCR4EPHX2METAP2METAP1CASR
SCHEMBL6653580 0.84 CXCR4 (0.72) CXCR4METAP2METAP1CASRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098215-B2 Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2006-08-29 US claimed
EP-1608318-A4 CXCR4 ANTAGONISTS AND METHODS OF THEIR USE UNIV EMORY (US) 2009-07-29 EP disclosed
US-20090036416-A1 Novel CXCR4 Antagonist and Use Thereof KYOTO UNIVERSITY (JP) 2009-02-05 US disclosed
US-20090036416-A1 Novel CXCR4 Antagonist and Use Thereof KYOTO UNIVERSITY (JP) 2009-02-05 US disclosed
US-7098215-B2 Nitrogenous compounds and antiviral drugs containing the same KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2006-08-29 US disclosed
EP-1608318-A2 CXCR4 ANTAGONISTS AND METHODS OF THEIR USE Emory University (US) 2005-12-28 EP disclosed
WO-2004087068-A2 CXCR4 ANTAGONISTS AND METHODS OF THEIR USE EMORY UNIVERSITY (US) 2004-10-14 WO disclosed
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound KUREHA CORPORATION (JP) 2004-08-12 US disclosed
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same KUREHA CORPORATION (JP) 2004-05-13 US disclosed
EP-1273571-A1 NITROGENOUS COMPOUNDS AND ANTIVIRAL DRUGS CONTAINING THE SAME Kureha Chemical Industry Co., Ltd. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092556-A1 Nitrogenous compounds and antiviral drugs containing the same NSUN2, ZC3HAV1L, PNP CXCR4 2185/4885EPHX2 3438/4885METAP2 1763/4885
US-20040157818-A1 Cxcr4-antagonistic drugs composed of nitrogen-containing compound CXCR4, CXCR1, CXCR2 CXCR4 1/4885EPHX2 2096/4885METAP2 4172/4885
US-20090036416-A1 Novel CXCR4 Antagonist and Use Thereof CXCR4, CXCR1, CXCL12 CXCR4 1/4885EPHX2 4289/4885METAP2 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.